Gabapentin, Tramadol and State-Level Controlled Substance Scheduling

Tramadol carries one federal classification nationwide. Gabapentin's classification, where it has one at all, is written state by state, on each legislature's own timeline. For a pharmacist-in-charge filling both drugs from the same bench, that gap drives real exposure. Tramadol's Schedule IV recordkeeping, inventory, and dispensing rules apply the same way in every state. Gabapentin can be an ordinary legend drug, a scheduled controlled substance, or a PDMP-reportable drug, depending on which state line the prescription crosses. Treating the two the same way invites a state board finding, or a diversion referral that starts as a paperwork gap.

Tramadol's Federal Schedule IV Status

Tramadol (2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol) is listed as DEA Controlled Substances Code Number 9752 under Schedule IV, confirmed against the DEA Diversion Control Division's own controlled substances list (deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf; codified at 21 C.F.R. § 1308.14). That classification does not vary by state. A tramadol prescription carries the same refill and quantity framework, the same DEA registration obligations, and the same suspicious order monitoring exposure for the dispensing pharmacy no matter where the patient fills it.

Why Gabapentin Sits Outside Federal Scheduling

The DEA has not placed gabapentin into any federal schedule. It remains a legend drug under federal law, dispensed on an ordinary prescription with no federal controlled-substance recordkeeping attached. States began moving on their own after reports of gabapentin misuse, particularly when combined with opioids, outpaced the federal schedule. The result is a state-by-state patchwork built entirely from individual legislatures and pharmacy boards acting without a federal scheduling action to anchor it.

The State-by-State Gabapentin Patchwork

A December 2025 academic analysis published in the National Library of Medicine's PMC archive, reviewing jurisdiction policy from January 2016 through December 31, 2024, found that seven jurisdictions had classified gabapentin as a Schedule V controlled substance by the close of that period. Kentucky was first, in July 2017, followed by West Virginia and Tennessee in 2018. A separate group of seventeen jurisdictions required gabapentin prescriptions to be reported to the state's prescription drug monitoring program (PDMP) without classifying the drug as controlled at all, a track Minnesota opened in August 2016. See HLA's PDMP obligations and enforcement coverage for how those reporting duties attach. In total, the study counted 25 jurisdictions, just under half of the fifty states and the District of Columbia, with some gabapentin policy on the books as of December 31, 2024.

The same study documents Michigan both scheduling gabapentin and later removing it from its own schedule within that study window, which is how fast the list moves. A pharmacist filling gabapentin across state lines should confirm the drug's current status with the state board of pharmacy or the state's own statutory text before assuming a multi-state summary, including this one, still matches the current session's law.

Tramadol's Schedule IV status travels with the drug. The law governing gabapentin can change at the state line.

Pharmacy and Prescriber Consequences of the Variation

Tramadol's Schedule IV status is fixed, so a pharmacy's corresponding-responsibility and perpetual inventory reconciliation obligations for tramadol look the same in every state the pharmacy operates. Gabapentin's state-dependent status means a multi-location pharmacy has to run two different compliance tracks from one central system: full Schedule V recordkeeping in a scheduling state, and PDMP reporting only in a state that monitors but does not schedule the drug. A pharmacy that files gabapentin as an ordinary legend drug in a state that has scheduled it, or skips a mandatory PDMP report where the state requires one, hands a state board a documented finding.

Combined gabapentin-and-opioid dispensing patterns can also surface during a suspicious order monitoring review that started with the pharmacy's tramadol or opioid volume. A pharmacy that cannot show it reconciled its controlled-substance inventory correctly is a harder target to defend once that review escalates into a DEA order to show cause against the registration itself.

Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.

Why Early Legal Counsel Is Critical

It is critical that healthcare providers promptly retain experienced healthcare defense counsel upon receiving a state board inquiry, a DEA request for records, or any other government inquiry tied to controlled-substance dispensing. Early legal intervention can protect the provider's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.

How Health Law Alliance Can Help: Health Law Alliance represents pharmacies and prescribers nationwide on DEA audit and registration defense, including the inventory and monitoring questions that tramadol's fixed federal schedule and gabapentin's shifting state status both raise. Contact us today for a free, confidential consultation.